Eosinophils chemotaxis to acetylsalicylic acid (ASA) is inhibited in aspirin-sensitive (ASA-S) asthmatics - possible role for lymphocyte involvement Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
Assessment of in vivo 5-lipoxygenase (5-LO) activity in nonatopic and atopic subjects with or without asthma: effects of treatment with the 5-LO inhibitor zileuton Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
15-LOXb is the enzymatic source of aspirin induced 15-HETE generation in aspirin-sensitive patients Source: Eur Respir J 2005; 26: Suppl. 49, 342s Year: 2005
Higher expression of lipoxygenase and cyclooxygenase pathways in bronchial than alveolar lavage from allergic asthmatics Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021
The influence of antileukotriene therapy with montelukast (M) on thromboxane B2 /leukotriene E4 (TXB2 /LTE4 ) ratio in the urine of asthmatic subjects and other inflammatory markers Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Imbalance of anti-inflammatory (resolving D1) and pro-inflammatory (leukotrien B4) arachidonic acid products in exhaled breath condensate of severe refractory asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011
Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Inhalation of mannitol, used as a model for exercise-induced bronchoconstriction (EIB), causes release of leukotrienes and a mast cell marker in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Eicosanoid concentrations in induced sputum (IS) in stable asthmatics with aspirin-tolerant (ATA) and aspirin-intolerant asthma (AIA) Source: Eur Respir J 2005; 26: Suppl. 49, 575s Year: 2005
Aminoguanidine inhibits bronchial NO production, but not diffusion or alveolar NO in patients with asthma, smokers and healthy volunteers Source: Eur Respir J 2004; 24: Suppl. 48, 577s Year: 2004
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response Source: Annual Congress 2011 - New treatments for airway disease Year: 2011
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Different expression of sphingosine 1-phosphate and lysophosphatidic acid receptors on neutrophils of pneumonia and healthy subjects; their role in neutrophils recruitment Source: Eur Respir J 2005; 26: Suppl. 49, 405s Year: 2005
Basophil activation test as support for distinguishing between aspirin-induced asthma and allergic reaction to ASA Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Lactose-β-sitosterol inhibits ovalbumin-induced asthmatic inflammation with no influence on nitric oxide pathway Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Effects of 5-lipoxygenase inhibitor on airway responses to inhaled organic dust in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 307s Year: 2002
Inhibition of the airway response to mannitol with either eformoterol or sodium cromoglycate (SCG) does not alter leukotriene release in asthmatic subjects Source: Eur Respir J 2004; 24: Suppl. 48, 443s Year: 2004